Dr. med. Anjali Cremer

Universitätsklinikum Frankfurt

Medizinische Klinik II/Abteilung für Hämatologie/Onkologie

Theodor-Stern Kai 7

60590 Frankfurt am Main


Exploitation of Oncogenic Mechanisms (EOM)

Molecularly Targeted Therapy (MTT)


Acute lymphocytic leukemia (ALL) is the second most common leukemia mainly occurring in two patient populations, a) in children under the age of 5 years and b) in adults over the age of 50 years. Although the traditional multiagent chemotherapy regimens induce high complete remission (CR) rates, many adult patients experience relapse of their disease. Despite the breakthrough advances of antibody-based therapies, the overall long-term survival rate for patients with relapsed or refractory ALL, as well as for certain genetic subtypes is still dismal emphasizing the need for novel, targeted treatment strategies. We are interested in dissecting the underlying mechanisms that confer resistance to targeted therapies in patients with acute leukemia.

By applying a multi-omics approach, as well as innovative screening strategies and complementing our results with clinical patient samples and data, our goal is to identify new oncogenic transcriptional networks in acute lymphoblastic leukemia (ALL) that can be therapeutically exploited. This will ultimately lead to new treatment strategies for patients with this disease.